Introduction
The BPC-157/TB-500 combination (known as the “Wolverine Stack”) is a synergistic dual-peptide blend designed to support tissue repair through complementary cellular mechanisms. BPC-157 promotes angiogenesis through VEGFR2 signaling while TB-500 enhances cell migration through G-actin regulation. With over 370 combined studies (200+ BPC-157 and 170+ TB-500), these are among the most researched regenerative peptides.
Mechanism of Action
VEGFR2 Pathway (BPC-157)
Promotes new blood vessel formation, increases blood flow to injured areas, and activates endothelial cell proliferation.
G-Actin Sequestration (TB-500)
Regulates cytoskeletal remodeling, facilitates cell motility and migration, and enables wound closure.
Anti-Inflammatory (Both)
Both peptides reduce pro-inflammatory cytokines and modulate NF-kB signaling through distinct pathways.
Research Findings
- BPC-157 cell migration: 70% faster
- TB-500 re-epithelialization: 61% faster
- BPC-157 GHR upregulation: 7x by day 3
- No LD50 established for either peptide
- TB-500 Phase 1: zero serious adverse events at doses up to 1260mg IV
No formal combination clinical trials exist. Synergistic potential is inferred from complementary mechanisms.
Research Areas
- Tendon & Ligament: BPC-157 fibroblast outgrowth combined with TB-500 cell migration
- Wound Healing: Angiogenesis (BPC-157) combined with keratinocyte migration (TB-500)
- Muscle Recovery: FAK/paxillin + actin regulation dual pathway support
- Anti-Inflammatory: NF-kB modulation from both peptides
Compound Information
- Type: Dual peptide blend
- BPC-157: 1,419.5 Da, 15 amino acids, CAS 137525-51-0
- TB-500: 4,963 Da, 43 amino acids, CAS 77591-33-4
Safety Profile
- Injection site reactions: 10% (mild)
- BPC-157: No lethal dose reached in preclinical toxicology
- TB-500: No serious adverse events at doses up to 1260mg IV
References
- Vasireddi N, et al. (2025) “Emerging Use of BPC-157 in Orthopaedic Sports Medicine” HSS Journal PMID: 40756949
- Goldstein AL, et al. (2012) “Thymosin beta-4: a multi-functional regenerative peptide” Expert Opin Biol Ther PMID: 22074294
- Chang CH, et al. (2011) “BPC 157 on tendon healing” J Applied Physiology PMID: 21030672
- Malinda KM, et al. (1999) “Thymosin beta4 accelerates wound healing” J Invest Dermatol PMID: 10469335
Disclaimer
FOR RESEARCH USE ONLY. Not for human consumption. All compounds are sold strictly for in vitro research and laboratory use. © Forto Labs